Major Organizations are focused on Offering Guidelines Regarding Management of Asthma and COPD during the Covid-19 Pandemic

 

Chronic obstructive pulmonary disease (COPD) is a group of progressive lung diseases, whereas asthma is a condition in which your airways narrow and swell and may produce extra mucus. There are many ways to treat asthma and COPD, but treatment varies by severity of the condition. Treatment includes a combination of medications, therapy, and physical exercise.

Market Dynamics

High prevalence of COPD is expected to propel growth of the global asthma and COPD market. For instance, according to a report by Global Initiative For Chronic Obstruction Disease’s 2018 report, Chronic obstructive pulmonary disease is expected to result in 4.5 million global deaths annually by 2030. Moreover, R&D of novel dry powder inhalation formulations is also expected to aid in growth of the market. For instance, in June 2020, researchers from University of Szeged, Hungary, developed carrier-based dry powder inhalation system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application.

Increasing investment in development of inhalation products is expected to offer lucrative growth opportunities for players in the global asthma and COPD market. For instance, in July 2020, CF PharmTech, Inc. raised US$ 50 million in Series F financing to accelerate the commercialization of its inhalation products for the treatment of respiratory diseases.

Major organizations are focused on offering guidelines regarding management of asthma and COPD during the Covid-19 pandemic. For instance, in July 2020, Asthma and Allergy Foundation of America released a comprehensive guide, the “COVID-19 and Asthma Toolkit for Schools” to help educators and families of children living with asthma navigate best methods to stay healthy for those returning to classrooms during the COVID-19 pandemic.

Among regions, Latin America is expected to witness significant growth in the asthma and COPD market, owing to high prevalence of asthma in the region. For instance, according to The Global Asthma Report 2018, the prevalence of asthma symptoms was 23% and the prevalence of a medical diagnosis of asthma 12% in Brazil.

Competitive Analysis

Major players operating in the global asthma and COPD market include, AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH.

July 2020: AstraZeneca's results from the positive Phase III ETHOS trial were published in the New England Journal of Medicine. The study demonstrated that the triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) reduced the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe COPD.